Blood-based biomarkers for Alzheimer’s disease in primary care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses a blood biomarker test to see how ptau217 and ptau217/Aβ42 results influence diagnostic pathways for adults aged 55–85 who visit their PCP with cognitive concerns. Participants provide a blood sample and complete standard clinical assessments as part of their diagnostic workup. The goal is to see if these biomarkers can inform decisions and trajectories in the care of potential Alzheimer’s disease. The study is conducted at KU Leuven and UZ Leuven in Leuven, Belgium, under the lead sponsor Universitaire Ziekenhuizen KU Leuven.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.

Exclusion Criteria:

* Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
* Concomitant medications that would interfere with cognitive assessments.
* A prior diagnosis of AD and related disorders or other neurodegenerative disease.

Where it's running

• UZ Leuven/KU Leuven
  Leuven, Belgium Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice

  This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.

  Recruiting Fudan University · Shanghai, Jingan · NCT07923812

• Automated language analysis to help diagnose neurodegenerative diseases

  A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Bari · NCT07906769

• LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment

  A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07866768

• Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement

  This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.

  Recruiting University Hospital, Akershus · Prague · NCT07842146

• Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease

  This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07803055

• Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases

  This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07798700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.